Genes with significant differential expression between the TMPRSS2-ERG positive and negative lesions were identified and validated by qRT-PCR in a larger series of prostate carcinomas, as well as by immunohistochemistry and chromatin immunoprecipitation analyses (ChIP). This evidence concerns the gene TMPRSS2 and prostate carcinoma.